Insys Therapeutics Given New $46.00 Price Target at Oppenheimer (INSY)
Stock analysts at Oppenheimer hoisted their target price on shares of Insys Therapeutics (NASDAQ:INSY) from $29.00 to $46.00 in a report issued on Wednesday, American Banking & Market News reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price objective would suggest a potential upside of 23.86% from the stock’s previous close.
Shares of Insys Therapeutics (NASDAQ:INSY) traded down 0.16% during mid-day trading on Wednesday, hitting $37.14. The stock had a trading volume of 117,233 shares. Insys Therapeutics has a 1-year low of $6.55 and a 1-year high of $37.80. The stock’s 50-day moving average is $26.33 and its 200-day moving average is $16.40. The company has a market cap of $795.0 million and a price-to-earnings ratio of 7.11.
Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings results on Tuesday, August 13th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.23. The company had revenue of $18.80 million for the quarter, compared to the consensus estimate of $15.07 million. Analysts expect that Insys Therapeutics will post $0.96 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on INSY. Analysts at JMP Securities set a $27.00 price target on shares of Insys Therapeutics (NASDAQ:INSY) in a research note to investors on Wednesday, August 14th. Separately, analysts at Zacks downgraded shares of Insys Therapeutics (NASDAQ:INSY) to a “neutral” rating in a research note to investors on Tuesday, August 6th. They now have a $18.60 price target on the stock. Finally, analysts at Wells Fargo & Co. initiated coverage on shares of Insys Therapeutics (NASDAQ:INSY) in a research note to investors on Wednesday, July 31st. They set an “outperform” rating on the stock.
Insys Therapeutics, Inc, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.